Insider trade

Officer received an award of 3,883 VRTX shares

Traded Jan 22, 2026 · Filed Jan 26, 2026

Vertex PharmaceuticalsVRTX

3,883
Shares

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jan 22, 2026
Reporting period: Not applicable
Filed with the SEC: Jan 26, 2026

OfficerGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0000875320-26-000026
Filed / recorded

Jan 26, 2026, 9:37 PM UTC

Added to OQRO

Oct 2, 2026, 12:29 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

VERTEX PHARMACEUTICALS INC / MA

Issuer CIK

875320

Ticker

VRTX

Reporting person

Ourania Tatsis

Relationship

Officer

Officer title

EVP, Chief Reg. & Quality Off.

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Jan 22, 2026

Transaction code

A

Shares / units

3,883

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

54,042

Ownership form

Direct

Amendment

No

Footnotes from the filing

Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.